IMS Health raises $1.3B in NY IPO

IMS Health raises $1.3 billion in its New York IPO.
IMS Health raises $1.3 billion in its New York IPO.

IMS Health raised $1.3 billion last month in its New York IPO. The company, which analysts expected would see shares go for between $18 and $21, sold 65 million shares at $20, according to VentureBeat.com.

Formerly public, IMS went private in 2010, after TPG Capital, Canada Pension Plan Investment Board (CPPIB) and Leonard Green & Partners bought it for $5.2 billion, including debt. After the offering, TPG's stake was set to be cut 50% from 62.2%, without underwriters exercising their full option.

The Danbury, CT-based company said it plans to use the offering's net proceeds for debt financing and general corporate purposes.

IMS's operating income rose to $276 million in the nine months ended September 30, 2013, from $173 million a year earlier. Revenue rose 4% to $1.9 billion.

You must be a registered member of MMM to post a comment.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.